Home Page

BOSTON, July 28, 2016 /PRNewswire/ -- BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced the promotion of the company's Financial Controller, Kevin Coveney, to the position of Vice President of Finance and Controller, upon the departure of Jason Haddock, Chief Financial Officer and Chief Operating Officer.

As Vice President of Finance and Controller, Coveney will be responsible for driving financial operations and will oversee corporate finance and accounting at BERG. He will report to BERG's Chief Executive Officer, Niven R. Narain.

Coveney has more than 25 years of financial experience. Prior to joining BERG in 2015 as Finance Controller, he was Assurance Services Principal at Wolf & Company, PC.  Previously, Coveney held senior level finance positions at Grant Thornton LLP, Braver PC, Ernst & Young among other institutions.

"I am personally thrilled to announce Kevin's promotion," said Niven R. Narain, BERG's Co-Founder, President and CEO. "BERG is entering the next phase of its expansion and Kevin's promotion is a key step in making sure that the company has the right team in place as we embark on our next chapter"

About BERG
BERG is a clinical-stage company disrupting and re-defining the approach to drug discovery, research and development through its Interrogative Biology® platform. Its platform identifies therapies and biomarkers by applying algorithm- and probability-based artificial intelligence to analyze large numbers of patients' genotypic, phenotypic and other characteristics. BERG's platform operates at the intersection of biology, technology and artificial intelligence analytics and integrates many data characteristics regarding patients' lifestyles, demographics and biology. BERG believes this allows the company to better understand patients' disease profiles and consequently to identify and reveal molecular signatures to guide and accelerate product candidate selection and development. By identifying biomarkers and patient characteristics that are unique to the disease state, BERG is able to identify novel therapeutic product candidates and develop companion diagnostics to enhance specificity in its drug development process.  

BERG has leveraged its Interrogative Biology® platform to develop a robust pipeline of therapeutic product candidates and diagnostics in cancer, diabetes and neurology. Its lead drug, BPM-31510 (IV), has the potential to slow or reverse cancer cell growth by changing a hypothesized fundamental driver of many different types of cancer.  BERG has initiated a Phase II clinical trial for BPM-31510 (IV) in advanced pancreatic cancer in combination with a common cancer drug, among other ongoing and planned trials for BPM-31510 (IV) in various oncological indications.

For additional information, please visit www.BERGhealth.com.

SOURCE BERG